InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

- Current share price for CYP : $0.010

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2 Site Initiation Visit Completed for CYP DFU Clinical Trial 18 Nov 2021 9:20AM $0.530 $0.010 fallen by 98.11%
$2 Results of Annual General Meeting 16 Nov 2021 1:55PM $0.550 $0.010 fallen by 98.18%
$2 AGM Presentations 16 Nov 2021 9:48AM $0.545 $0.010 fallen by 98.17%
$2 Quarterly Activity Report & Appendix 4C 28 Oct 2021 12:42PM $0.600 $0.010 fallen by 98.33%
$2 Cynata Receives US$5m Fujifilm Fee 18 Oct 2021 9:33AM $0.630 $0.010 fallen by 98.41%
$2 Annual Report to shareholders 14 Oct 2021 5:17PM $0.610 $0.010 fallen by 98.36%
$2 Letter to Shareholders & Notice of Annual General Meeting 14 Oct 2021 5:07PM $0.610 $0.010 fallen by 98.36%
$2 Notification regarding unquoted securities - CYP 12 Oct 2021 5:13PM $0.610 $0.010 fallen by 98.36%
$2 DSMB Recommends Continuation of Cynata's MEND Trial 8 Oct 2021 9:23AM $0.625 $0.010 fallen by 98.40%
$2 Cynata Enters into a New Strategic Partnership with Fujifilm 30 Sep 2021 2:02PM $0.550 $0.010 fallen by 98.18%
$2 CYP Preclinical Heart Attack Study Published in Cytotherapy 28 Sep 2021 9:29AM $0.525 $0.010 fallen by 98.10%
$2 Date of AGM and Closing Date for Director Nominations 21 Sep 2021 4:48PM $0.510 $0.010 fallen by 98.04%
$2 Further Patents for Cynata Unique Cymerus Technology 15 Sep 2021 12:38PM $0.540 $0.010 fallen by 98.15%
$2 Further Canadian Patent for Cynata 31 Aug 2021 9:00AM $0.515 $0.010 fallen by 98.06%
$2 Appendix 4G 30 Aug 2021 12:56PM $0.523 $0.010 fallen by 98.09%
$2 Appendix 4E & Annual Report 30 Aug 2021 12:55PM $0.523 $0.010 fallen by 98.09%
$2 Cynata Receives Notice of Allowance from US Patent Office 26 Aug 2021 1:24PM $0.510 $0.010 fallen by 98.04%
$2 Quarterly Activity Report & Appendix 4C 28 Jul 2021 9:07AM $0.510 $0.010 fallen by 98.04%
$2 Cynata Appoints Dr Jolanta Airey Chief Medical Officer 26 Jul 2021 11:19AM $0.480 $0.010 fallen by 97.92%
$2 Change of Registered Office 5 Jul 2021 5:35PM $0.520 $0.010 fallen by 98.08%
$2 Ethics Approval for Cynata's Clinical Trial in DFU 30 Jun 2021 9:49AM $0.515 $0.010 fallen by 98.06%
$2 Progress Toward Clinical Trial in Diabetic Foot Ulcers 28 Jun 2021 9:20AM $0.520 $0.010 fallen by 98.08%
$2 Cynata to Present at MST Access Investor Conference 15 June 11 Jun 2021 2:41PM $0.560 $0.010 fallen by 98.21%
$2 Cynata signs Licence Agreement with TekCyte 3 Jun 2021 11:09AM $0.565 $0.010 fallen by 98.23%
$2 Release of Securities from Voluntary Escrow 28 May 2021 5:38PM $0.590 $0.010 fallen by 98.31%

276 - 300 of 721 results

Page 12 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.